Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside

SummaryWith paid stock promotion CBMG has achieved an unsustainable $500m valuation, and with $20m in stock sold and insiders stock registered to sell, I expect CBMG will continue to collapse.
CBMG “Car-T” technology was acquired for $1.8m, has experienced patient deaths and is worthless. CBMG recent R&D of just $4.9m makes the $500m valuation clearly absurd.
CBMG founders face dishonesty allegations, are […]

Re: Technical Analysis and Individual Investors – All Star Charts with …

Re: Technical Analysis and Individual InvestorsPosted by JC Parets
on March 19th, 2014

Share on StockTwitsI’m going to keep this short and sweet. I don’t think it’s worth dedicating more than a couple of minutes to commenting this study. I’m referring to last month’s release of a paper written by Arvid Hoffman and Hersh Shefrin titled, […]